Clinical Trial Update: The Effect of Nafamostat Mesilate in Prolonging Filter Patency With Patients on Continuous Renal Replacement Therapy [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating nafamostat mesilate for prolonging filter patency in patients undergoing continuous renal replacement therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Drugs mentioned

• Nafamostat Mesilate (Nafamostat mesilate)

Snippet

Sponsor: Yonsei University | Conditions: Acute Kidney Injury | Phase 4 | Status: COMPLETED